Mannkind Corporation · NASDAQ:MNKD

Mannkind — Corporate Update (July 2026)

23 slides from Mannkind's corporate update, Jul 24, 2026

Slide 2: Cautionary Statement
Cautionary Statement Statements in this presentation that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. Words such as “believes”, “anticipates”, “plans”, “expects”, “intend”, “will”, “goal”, “potential” and similar expressions are intended
Slide 3: Agenda
Agenda 1 Approval 2 Launch Strategy 3 Clinical Overview Michael Castagna Ajay Ahuja, MD 4 Closing Remarks Chief Executive Officer Chief Medical Officer 5 Q&A 3 © Copyright 2026. All rights reserved. MannKind Corporation. / 24 July 2026
Slide 5: Highlights
Highlights • Furoscix ReadyFlow Now Approved • Announced PIPE financing of $50 million led by Frazier Life Sciences o Supports the $45 million contingent value rights payment triggered by FDA approval of Furoscix ReadyFlow 5 © Copyright 2026. All rights reserved. MannKind Corporation.
Slide 6: Furoscix ReadyFlow Now Approved
Furoscix ReadyFlow Now Approved The first and only IV-equivalent diuretic delivered via autoinjector Designed for at-home intervention • Treats fluid overload in adults with HF or CKD outside the hospital setting • May support earlier intervention beyond the hospital – across outpatient, post-discha
Slide 7: Furoscix Can Address Fluid Overload Across the Patient Journey
Furoscix Can Address Fluid Overload Across the Patient Journey STABLE PATIENT TREATED AT HOME WITH ORAL DIURETIC POST-HOSPITAL DISCHARGE Use Furoscix to: • Discharge early and resolve residual congestion at home ~1M EARLY INTERVENTION When fluid overload first Addressable • Treat relapse congestion
Slide 8: HF and CKD Place a Significant Economic Burden on the U.S. Healthcare System
HF and CKD Place a Significant Economic Burden on the U.S. Healthcare System Heart Failure Chronic Kidney Disease Direct medical costs from heart ~15% of Medicare FFS beneficiaries have failure in the U.S. is projected to diagnosed CKD, yet they account for ~27% approach $70B by 20301 of total spend
Slide 9: CMS is Now Putting Specialists on the Hook for HF Costs
From Hospitals to Cardiologists: CMS is Now Putting Specialists on the Hook for HF Costs Hospital Readmission Ambulatory Specialty What It Means For Furoscix Reduction Program (HRRP) Model (ASM) Ambulatory cardiology Reinforces at-home Furoscix use Care Setting Inpatient hospitals (Medicare FFS) out
Slide 11: Ajay Ahuja, MD, MBA
Ajay Ahuja, MD, MBA Executive Vice President, Chief Medical Officer Cardiologist with 20+ years of biopharmaceutical leadership across cardiometabolic and respiratory diseases • Leads MannKind's clinical development and medical activities across cardiometabolic and respiratory therapeutic areas • Jo
Slide 12: Pivotal PK/PD Study Compared Furoscix ReadyFlow With IV Furosemide
A Pivotal PK / PD Study Compared Furoscix ReadyFlow With IV Furosemide in Healthy Adult Volunteers The pivotal PK/PD study was a prospective, randomized, non-blinded crossover study 80 mg IV furosemide 80 mg SC Furoscix ReadyFlow Endpoints: (40 mg over 2 min; (80mg/1mL over 5-10 seconds) • Plasma Ra
Slide 13: Furoscix ReadyFlow Achieved Its Primary Pharmacokinetic Endpoint
Furoscix ReadyFlow Achieved Its Primary Pharmacokinetic Endpoint Bioavailability: 107.3% (90% CI: 103.9 – 110.8) SC ReadyFlow IV Furosemide (n=19) * (n=19)* Cmax (ng/mL) 4,533 + 1,498 10,088 + 2,805 AUClast 12,470 + 4,010 11,684 + 3,453 (hr*ng/mL) AUCinf 12,714 + 4,117 11,780 + 3,507 (hr*ng/mL) T1/2
Slide 14: Furoscix ReadyFlow Achieved Its Secondary Pharmacodynamic Endpoints
Furoscix ReadyFlow Achieved Its Secondary Pharmacodynamic Endpoints Equivalent Urine Output at 6, 8, and 12 hours as compared to IV furosemide 6 IV furosemide SC ReadyFlow p-value N=19* N=19* Mean (SD) Total Urine Output, L 5 Urine Output (mean (SD) Liters) 4 0-6 hours 2.91 (0.72) 3.19 (0.88) 0.27 3
Slide 15: Study Conclusions
Study Conclusions • Furoscix ReadyFlow administered via an autoinjector achieved the bioavailability primary endpoint • Furoscix ReadyFlow administered via an autoinjector achieved the pharmacodynamic secondary endpoints • Furoscix ReadyFlow was generally well tolerated with respect to injection sit
Slide 17: Furoscix ReadyFlow May Expand Who Is Treated And Enable Earlier Intervention
Furoscix ReadyFlow May Expand Who Is Treated And Enable Earlier Intervention REDUCES TREATMENT BROADENS PATIENT FIT SUPPORTS EARLIER BURDEN INTERVENTION Administration time in Simplicity may expand who Convenience may reduce seconds vs. hours creates a is considered appropriate hesitation as symptom
Slide 18: Furoscix ReadyFlow Launch Campaign Is Built to Drive Immediate Awareness and Adoption
Furoscix ReadyFlow Launch Campaign Is Built to Drive Immediate Awareness and Adoption Field activation begins immediately • Sales force launch training and deployment underway • Integrated HCP and patient campaign ready across digital, field and point-of-care channels • Major cardiology and nephrolo
Slide 19: Furoscix ReadyFlow Approval Enables a Pathway for IDN Growth
Furoscix ReadyFlow Approval Enables a Pathway for IDN Growth 01 Establish 02 Embed 03 Expand Engage priority IDNs Integrate into care Scale across the pathways health system Build awareness and Support discharge, post- Reach more patients, clinical confidence discharge and outpatient providers and c
Slide 21: Major Catalysts Driving 2026 & Beyond
Major Catalysts Driving 2026 & Beyond Afrezza Pediatrics Furoscix ReadyFlow Nintedanib DPI Autoinjector • Population expansion • Reduces administration from • Urgent need for new, effective hours to seconds therapies in IPF • Unique value proposition addressing patient unmet • Supports broader adopt

MannKind — Corporate Update (July 2026) on 6ix

Mannkind — Corporate Update (July 2026)

Slide 1: U.S. FDA Approval of Furoscix ReadyFlow

Slide 2: Cautionary Statement

Slide 3: Agenda

Slide 4: Approval of Furoscix ReadyFlow

Slide 5: Highlights

Slide 6: Furoscix ReadyFlow Now Approved

Slide 7: Furoscix Can Address Fluid Overload Across the Patient Journey

Slide 8: HF and CKD Place a Significant Economic Burden on the U.S. Healthcare System

Slide 9: CMS is Now Putting Specialists on the Hook for HF Costs

Slide 10: Clinical Overview

Slide 11: Ajay Ahuja, MD, MBA

Slide 12: Pivotal PK/PD Study Compared Furoscix ReadyFlow With IV Furosemide

Slide 13: Furoscix ReadyFlow Achieved Its Primary Pharmacokinetic Endpoint

Slide 14: Furoscix ReadyFlow Achieved Its Secondary Pharmacodynamic Endpoints

Slide 15: Study Conclusions

Slide 16: Launch Strategy

Slide 17: Furoscix ReadyFlow May Expand Who Is Treated And Enable Earlier Intervention

Slide 18: Furoscix ReadyFlow Launch Campaign Is Built to Drive Immediate Awareness and Adoption

Slide 19: Furoscix ReadyFlow Approval Enables a Pathway for IDN Growth

Slide 20: Closing Remarks

Slide 21: Major Catalysts Driving 2026 & Beyond

Slide 22: Q&A

Slide 23: © Copyright 2026. All rights reserved. MannKind Corporation.